NCI advisors approve recompetition of $62 million phase II contracts program.
Also AIDS Malignancy Consortium grants to be consolidated on recompetition to one central group chairman’s office.
Advisors approve set-aside for alternative medicine “best case series.”
HHS bans tobacco from its campuses, opens national quitline, 1-800-QUITNOW.
Two founding cancer center directors step down: Harold Moses at Vanderbilt-Ingram and Charles Coltman at CTRC.
Funding opportunities listed.
November issue of Business & Regulatory Report, an additional 8 pages, included in this issue.
Trending Stories
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- In the Headlines: Is oncology ready to move away from animal testing?
- Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad
- Imaging’s ride to the bottom in clinical trials—and why it matters now
- Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya - Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out